Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Abstract

Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. Methods In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine. We also compared infection rates in a subset of vaccinated individuals subsequently tested for SARS-CoV-2 with PCR or lateral flow tests with infection rates in unvaccinated controls. All analyses were adjusted by age (≤55 years vs >55 years), sex, health-care worker status (binary variable), obesity (BMI <30 kg/m 2 vs ≥30 kg/m 2 ), and comorbidities (binary variable, with or without comorbidities). Findings Between Dec 8, and March 10, 2021, 627 383 individuals reported being vaccinated with 655 590 doses: 282 103 received one dose of BNT162b2, of whom 28 207 received a second dose, and 345 280 received one dose of ChAdOx1 nCoV-19. Systemic side-effects were reported by 13·5% (38 155 of 282 103) of individuals after the first dose of BNT162b2, by 22·0% (6216 of 28 207) after the second dose of BNT162b2, and by 33·7% (116 473 of 345 280) after the first dose of ChAdOx1 nCoV-19. Local side-effects were reported by 71·9% (150 023 of 208 767) of individuals after the first dose of BNT162b2, by 68·5% (9025 of 13 179) after the second dose of BNT162b2, and by 58·7% (104 282 of 177 655) after the first dose of ChAdOx1 nCoV-19. Systemic side-effects were more common (1·6 times after the first dose of ChAdOx1 nCoV-19 and 2·9 times after the first dose of BNT162b2) among individuals with previous SARS-CoV-2 infection than among those without known past infection. Local effects were similarly higher in individuals previously infected than in those without known past infection (1·4 times after the first dose of ChAdOx1 nCoV-19 and 1·2 times after the first dose of BNT162b2). 3106 of 103 622 vaccinated individuals and 50 340 of 464 356 unvaccinated controls tested positive for SARS-CoV-2 infection. Significant reductions in infection risk were seen starting at 12 days after the first dose, reaching 60% (95% CI 49–68) for ChAdOx1 nCoV-19 and 69% (66–72) for BNT162b2 at 21–44 days and 72% (63–79) for BNT162b2 after 45–59 days. Interpretation Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days. Funding ZOE Global, National Institute for Health Research, Chronic Disease Research Fo...

Uncommon Presentation of COVID-19 With Long Incubation Period and Only Gastrointestinal Symptoms in a Fully Vaccinated Patient: Is There a Relation?

“…Menni et al studied the risk of infection after COVID-19 vaccination and reported that those older than 55 years of age had a much lower risk of getting infected after the vaccine. In addition, patients with multiple comorbidities had a higher chance of getting infected than those with no comorbidities post-vaccination [9]. However, our patient did not have any comorbid disease and was 33 years old.…”

“…History of GERD with a positive status of vaccine should not eliminate the possibility of contracting COVID-19. Infection cases post-vaccination have been reported to occur in a less aggressive form of the disease [9]. Menni et al studied the risk of infection after COVID-19 vaccination and reported that those older than 55 years of age had a much lower risk of getting infected after the vaccine.…”

Subacute Thyroiditis After Receiving the Adenovirus-Vectored Vaccine for Coronavirus Disease (COVID-19)

“…The common side effects of these vaccines, such as pain in the injected site, allergic skin reactions, flu-like symptoms, headache, fatigue and fever, have been well documented [ 9 , 10 ]. A large study revealed that the systemic and local side-effects from receiving COVID-19 vaccination occurred at frequencies lower than reported in the phase-3 trials [ 11 ].…”

Impact of vaccination in reducing Hospital expenses, Mortality and Average length of stay among COVID-19 patients – a retrospective cohort study from India

“…Even among those with comorbidities, a single dose was able to significantly reduce ALOS and hospital expenses. Studies [12] have shown 60-70% reduction in infection risk starting 12 days after the first dose. Tyagi et al [4] in a survey among health care workers, with a higher viral load, reported 17% break through infections post vaccination, although all of them were mild.…”